Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Events

08 Dec 2026 - 10 Dec 2026
25 Jan 2027 - 28 Jan 2027

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

By HospiMedica International staff writers
Posted on 14 Sep 2026

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. More...

Standard biomarkers, including programmed death-ligand 1 (PD-L1) expression, microsatellite instability, and tumor mutational burden, provide incomplete and inconsistent guidance across tumor types. Integrating molecular, cellular, imaging, and clinical signals could more fully capture dynamic tumor-immune interactions. A new review in Science Bulletin outlines how multimodal AI can support this integration, presenting a multi-scale framework to guide patient selection, toxicity prediction, and future model evaluation.

Researchers at Army Medical University (Chongqing, China) led the review, “Emerging Advances in Multimodal AI in Cancer Immunotherapy: From Multi-Scale Data Integration to Clinical Decision Support,” which identifies multimodal artificial intelligence as a pathway to unify disparate datasets for clinical decision support. The article describes how models can connect genomics, transcriptomics, proteomics, epigenomics, single-cell and spatial omics, digital pathology, radiological imaging, and longitudinal electronic health records to refine treatment choices and anticipate adverse events. By learning nonlinear relationships across scales, these systems aim to move beyond single biomarkers toward composite patient representations.

Methodologically, the authors map six connected stages: early machine learning classifiers; unsupervised representation learning with autoencoders, variational autoencoders, and contrastive learning; graph-based modeling of cell-cell and molecular interactions; multimodal foundation models and biomedical language models; reinforcement and active learning for dynamic optimization; and “AI virtual cells” that learn cellular states and predict responses to perturbations.

At the molecular and cellular levels, integrated models can characterize cellular composition, functional states, spatial neighborhoods, and communication networks within the tumor immune microenvironment. The review also highlights applications such as AI-assisted virtual staining, cellular phenotyping, and spatial multi-omics integration to maximize information from limited tissue.

At the clinical interface, digital pathology models using H&E whole-slide images and immunohistochemistry have been explored to infer PD-L1 status, microsatellite instability, tumor mutational burden, immune infiltration, treatment response, and prognosis. Radiomics and deep-learning analyses of CT, PET, and MRI can derive phenotypic features associated with response, progression, recurrence, survival, and immune-related adverse events. Longitudinal multimodal analysis may further help distinguish pseudoprogression from true progression or hyperprogression by integrating imaging, pathology, molecular states, and clinical trajectories.

The review emphasizes modeling efficacy and toxicity together to support therapy selection, follow-up planning, and timely intervention. Key barriers include asynchronous data collection, missing modalities, distribution shifts across institutions and devices, shortcut learning, and suboptimal multimodal fusion. Many studies remain retrospective and single-center with limited external validation and variable endpoints, and concerns persist around model opacity, hallucinations, causal interpretation, and insufficient biological validation.

To advance translation, the authors call for multicenter, temporal, and real-world validation, including explicit testing of missing-modality robustness, data drift, calibration, and predictive uncertainty. They also recommend decision-curve analysis and net-benefit assessment to evaluate clinical utility.

The article underscores the need for transparent data provenance, interoperability, privacy protection, and lifecycle monitoring, supported by functional experiments, prospective studies, and clinical trials. AI virtual cells will also require high-quality perturbation datasets, standardized benchmarks, and closed-loop iteration with experiments. Overall, the work positions AI as an assistive tool for organizing cancer immunotherapy around integrated efficacy-toxicity decision support rather than isolated biomarkers.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Pediatric Mask
Respire SOFT
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image Credit: Shutterstock

Explainable AI Examines Sepsis Mortality Risk and Emergency Care Delays

Preventing sepsis-related deaths in emergency departments (EDs) remains challenging because patient deterioration can result from multiple rapidly evolving and interconnected factors. These include triage... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image: A new automated approach could help predict which patients with dystonia will benefit from deep brain stimulation before surgery (Image Credit: Adobe Stock)

AI Uses Routine MRI to Predict Deep Brain Stimulation Response in Dystonia

Dystonia is a debilitating neurological movement disorder characterized by involuntary muscle contractions that cause abnormal movements and postures. Deep brain stimulation (DBS) is one of the few treatments... Read more

Health IT

view channel
Image Credit: Shutterstock

Telemonitoring Program Improves Quality of Life After Heart Failure Discharge

Heart failure is a chronic condition associated with high mortality, frequent hospitalizations, and reduced quality of life. Patients face particularly high risks of readmission and death after discharge,... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.